Obalon Therapeutics (NASDAQ:OBLN) reported Q3 sales of $44.00 thousand. Earnings fell to a loss of $1.56 million, resulting in a 62.5% decrease from last quarter. Obalon Therapeutics collected $703.00 thousand in revenue during Q2, but reported earnings showed a $4.16 million loss.
Changes in earnings and sales indicate shifts in Obalon Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Obalon Therapeutics posted an ROCE of -0.26%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For Obalon Therapeutics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.
Obalon Therapeutics reported Q3 earnings per share at $-0.2/share, which did not meet analyst predictions of $-0.07/share.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。